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Scope of the paper
We present a novel valuation model based on real options
1 that incorporates the impact of external forces, such as market
conditions, economic uncertainty, innovation, firm competition on the
cash flow generation
2 that features an option to abandon
3 that enables to estimate the impact of these external conditions on
the optimal launching time for the project as well as on success or
failure rates of the project
Our practical case covers a pharmaceutical R&D project, but the model
and methodology can be easily extrapolated to any industry





Scope of the paper
The literature has shown the economic and social impact of R&D projects
as well as the impact of the economic and social context on R&D
spending
International context, GDP as determinants of public spending in
research and developments (Hammadou et al., 2014, RP)
Eﬀect of public funding on innovative projects (Lanahan and
Feldman, 2017, RES)
Productivity growth and R&D expenses (e.g. Kancs an Siliverstovs,
2016, RP)
Social and economic impact of R&D (e.g. Brautzsch et al., 2015, RP;
Ugur et al., 2016, RP)





1 R&D valuation model
Literature Review





Practical case v2 (new)
3 Concluding remarks






Our contribution: modeling external forces
Project’s value
R&D valuation model






Our contribution: modeling external forces
Project’s value
Theoretical framework
In the extant literature, real options have been used to model
staged investments (e.g. Madj and Pindyck, 1987, JFE; Berk et al.,
2004, RFS)
the optimal timing of investments (e.g. McDonald and Siegel, 1986,
QJE; Posner and Zuckerman, 1990, JAP)
the impact of uncertainty in cash flows and cost on the project’s value
and risk (e.g. Schwartz, 2004, EN; Berk et al., 2004, RFS)










Modeling project’s market value (e.g. Madj and Pindyck, 1987, JFE;
Pennings and Sereno, 2011, EJOR; Alexander et al., 2012, EJOR)
Modeling project’s cash flows (e.g. Berk et al., 2004, RFS; Schwartz,
2004, EN)
Modeling cost of completion and expenditures (e.g. DiMasi et al.,
2003, JHE; Pindyck, 1993, JFE; McDonald and Siegel,1986, QJE)
Modeling technical risk (e.g. Schwartz, 2004, EN ; Pindyck, 1993,
JFE ; Pennings and Sereno, 2011, EJOR)






Our contribution: modeling external forces
Project’s value
Theoretical framework
In the literature, it is common to model the evolution of the project or the
evolution of the cash flow as a stochastic diﬀerential equation...




These models account for market uncertainty and idiosyncratic risk of the
project but not for external cyclical forces






Our contribution: modeling external forces
Project’s value
Theoretical framework
To account for technical risk, we generalize the Poisson distribution...
Probability of success = e−λ












Our contribution: modeling external forces
Project’s value
Theoretical framework
The expected project value conditional to technical risk is given as




Assuming V (k = 1, 2, ...,∞) = 0
During the development process the discount factor is given by
e−rd t = e−(r+λˆ)t






Our contribution: modeling external forces
Project’s value
Theoretical framework
All these models share the same source of uncertainty...
A random walk weighted by σ(C , t) for capturing market and
idiosyncratic risk
A Poisson distribution to account for technical risk
No model accounts for...
Seasonal eﬀects
Business cycle
Other relevant external forces






Our contribution: modeling external forces
Project’s value
Economic and market external forces
Consider the net cash flow stream of a successful project
Ct = f (t) + Yt
Where
dYt = µdt + σdWt ⇒ Arithmetic Brownian motion
f (t) = Fourier series
The net cash flow of a successful project is given by an arithmetic Brownian
motion process plus a time-dependent component depicted by a Fourier series.
The Fourier series is a function defined as the sum of a set of simple sines and
cosines, representing all the forces that impact the generation of cash flows.






Our contribution: modeling external forces
Project’s value
Cash flow generation











where WQt is a standard Wiener process under the risk-neutral measure
PQ.






Our contribution: modeling external forces
Project’s value
State vector
Let’s define the economic state vector...
Φ(j) with j ∈ N
Each state...






Our contribution: modeling external forces
Project’s value
State vector
Let’s define the economic state vector...
Φ(j) with j ∈ N
Each state...
corresponds to a specific scenario
described by the cyclicality and the phase of the economic forces






Our contribution: modeling external forces
Project’s value
Patent value






















Practical case v2 (new)
Simulation exercise







Practical case v2 (new)
Pharmaceutical project’s stages
Two major phases...
1 Research and development phase
2 Market phase
The failure of one stage leads to overall project termination. We assume
that once the project successfully passes every test and stage of the R&D
process and finally achieves regulatory approval, technical risk virtually
vanishes.







Practical case v2 (new)
Economic forces
For the sake of simplicity let’s assume two economic forces...
1 US Gross domestic product (GDP)
The business cycle is defined as the cyclical movement of the GDP
around its long-term trend
Hodrick-Prescott (1997) filter to disentangle the cyclical behaviour
from the long-term trend
278 quarterly GDP observations ranging from January 1947 to April
2016, obtained from the Federal Reserve Bank of St. Louis web page
2 VIX index
Barometer of investor sentiment and market volatility
Hodrick-Prescott (1997) filter
1990-2016, monthly observations provided by the Chicago Board
Options Exchange (CBOE)







Practical case v2 (new)
GDP cyclical component
Time


















Peak at a frequency of 0.1871Hz
Representing a cyclical period of 5.35 years







Practical case v2 (new)
Volatility cycle
Time














VIX short- to medium-term cyclical component
Two dominating peaks with period of 1.4 and 3.8 years







Practical case v2 (new)
Volatility cycle
Time










VIX demeaned long-term component
Frequency (Hz)









Representing a long term period of 13.25 years (0.0755 Hz)







Practical case v2 (new)
Amplitude parameter
We use two well known Pharmaceutical Indexes:
S&P 500 Pharmaceutical Index
NYSE ARCA Pharmaceutical Index
Ranging from July 1992 to April 2016
S5PHAR Index DRG Index
GDP cyclical component 0.4907 (<0.001) 0.5011 (<0.001)
VIX cyclical component 0.0932 (0.195) 0.0913 (0.192)
VIX long-term component 0.3440 (<0.001) 0.3151 (<0.001)
R2 0.1275 0.1350







Practical case v2 (new)
Simulation exercise
Project’s net cash flow when launching
at the peak of the cycle and entering into recession, that is φ = 0
at the trough of the cycle and entering into the recovery phase, that
is φ = π
at an intermediate phase, φ = π/2







Practical case v2 (new)
Simulation exercise - Business cycle
Business cycle impact on the project’s net cash flow is modeled as
f (t) = 100 {0.4959 cos (1.1753 · t + φ1)}







Practical case v2 (new)
Simulation exercise - Business cycle
Conditional Expected Patent Value. Business cycle
Business Cycle Panel
Phase A B
V (t,Ct , It ;φ1 = 0) 908.7 (3.2) 604.1 (4.3)
V (t,Ct , It ;φ1 = π) 2553.7 (4.2) 2522.3 (4.4)
V (t,Ct , It ;φ1 = π/2) 1584.4 (3.9) 1486.2 (4.4)
Table: This table presents the patent value conditional to the phase parameter in
the business cycle.
Panel A: With abandon option
Panel B: Without abandon option







Practical case v2 (new)
Simulation exercise - Business and volatility cycles
π
3π/4

































Practical case v2 (new)
We perform a new exercise fitting the parameters of the fourier series to
cash flow data of pharmaceutical firms active in anti-infective drug
New external forces are assumed to better impact a specific
pharmaceutical project
Economic and political (business cycle and economic policy uncertainty
index)
Innovation (R&D expenditure as % of GDP, patent applications)
Health expenditures (per capita, out of pocket)
Competition (H concentration index based on sales)







Practical case v2 (new)
New simulation exercise
We consider the impact of these forces on a hypothetical project’s success,
abandon rate and value
The project has an initial cash-flow of 100 M$ (50 M$ standard deviation)
per quarter with an initial cost to completion equal to 1000 M$ (sigma =
0.5)
US versus Europe (EU)
Big versus small caps







Practical case v2 (new)
External forces
Figure: Spectral analysis EU EPU
Time










Cyclical component EPU in Europe
Frequency (Hz)















Practical case v2 (new)
External forces
Figure: Spectral analysis US EPU
Time








Cyclical component EPU in United States
Frequency (Hz)














Practical case v2 (new)
External forces
Figure: Spectral analysis EU Concentration
Time









Cyclical component concentration index in Europe
Frequency (Hz)















Practical case v2 (new)
External forces
Figure: Spectral analysis US concentration
Time






Cyclical component concentration index in United States
Frequency (Hz)
















Practical case v2 (new)
External forces
Table: Cyclical components of external factors
Panel: United States
Angular Freq (ω) Frequency (f ) Period
Economic Policy Uncertainty 1.7093 0.2720 3.68
Gross Domestic Product 1.1504 0.1831 5.46
Research and development expenditure (% of GDP) 0.6283 0.1000 10.00
Patent applications 1.0472 0.1667 6.00
Health expenditure per capita 0.3142 0.0500 20.00
Out of pocket health expenditure 0.9425 0.1500 6.67
Concentration 0.8378 0.1333 7.50







Practical case v2 (new)
External forces
Table: Cyclical components of external factors
Panel: Europe
Angular Freq (ω) Frequency (f ) Period
Economic Policy Uncertainty 2.2235 0.3539 2.83
Gross Domestic Product 1.0927 0.1739 5.75
Research and development expenditure (% of GDP) 0.6283 0.1000 10.00
Patent applications 0.4654 0.0741 13.50
Health expenditure per capita 0.3142 0.0500 20.00
Out of pocket health expenditure 0.9425 0.1500 6.67
Concentration 0.4189 0.0667 15.00







Practical case v2 (new)
Peer group analysis
Table: CF structure - Descriptive Statistics
Anti-infective Pharmaceutical Market
EU: 13 US:6
Average quarterly Cash-Flow 817 120





Average quarterly Cash-Flow 1748 13
Standard Deviation 950 28
Maximum 3667 105
Minimum 11 -44







Practical case v2 (new)
Fitting forces to cash flow structure
Table: Factors and amplitudes
Panel: Anti-infective
EU Market US Market
Amplitude Phase Amplitude Phase
Economic Policy Uncertainty 1 (0.11) 5.9540 3 (0.01) 4.1818
Gross Domestic Product 14 (0.08) 0.6388 12 (0.01) 4.0168
Research and development expenditure (% of GDP) 18 (0.09) 3.1704 88 (0.01) 0.8577
Patent applications 9 (0.01) 4.2222 48 (0.04) 5.7576
Health expenditure per capita 47 (0.01) 2.1413 69 (0.01) 0.0000
Out of pocket health expenditure 17 (0.03) 0.4525 26 (0.05) 3.1786
Concentration 47 (0.01) 5.6940 81 (0.02) 3.1416
This table presents the standardized amplitude parameter (p-value) of each factor







Practical case v2 (new)
Fitting forces to cash flow structure
Table: Factors and amplitudes
Panel: Europe
Big Cap Small Cap
Amplitude Phase Amplitude Phase
Economic Policy Uncertainty 7 (0.10) 5.9540 1 (0.37) 5.9540
Gross Domestic Product 10 (0.14) 0.6388 27 (0.11) 3.7804
Research and development expenditure (% of GDP) 18 (0.05) 3.1704 33 (0.19) 0.0288
Patent applications 15 (0.01) 1.0806 41 (0.22) 4.2222
Health expenditure per capita 107 (0.01) 2.1413 166 (0.01) 5.2829
Out of pocket health expenditure 16 (0.16) 0.4525 40 (0.16) 3.5941
Concentration 94 (0.01) 5.6940 100 (0.07) 2.5524
This table presents the standardized amplitude parameter (p-value) of each factor







Practical case v2 (new)
Launching time in US
Figure: All firms














Research and development expenditure










Health expenditure per capita 




Out of Pocket Health expenditure












Practical case v2 (new)
Launching time in EU
Figure: All firms














Research and development expenditure











Health expenditure per capita 




Out of Pocket Health expenditure












Practical case v2 (new)
Launching time in EU
Figure: Big Caps EU















Research and development expenditure









Health expenditure per capita 




Out of Pocket Health expenditure













Practical case v2 (new)
Launching time in EU
Figure: Small Caps EU














Research and development expenditure










Health expenditure per capita 




Out of Pocket Health expenditure












Practical case v2 (new)
Simulation analysis
Hypothetical project (for every group): initial cash-flow of 100 M$ (50 M$
std dev) per quarter and initial cost to completion of 1000 M$ (std dev =
0.5)




A B A B
Launching at t = 0y 797.6 (4.5) 390.2 (5.8) 945.0 (4.8) 640.3 (5.9)
Abandon rate 50.77% - 42.33% -
Launching at t = 1y 621.9 (3.9) 73.2 (5.7) 750.3 (4.2) 333.3 (5.7)
Abandon rate 58.16% - 49.70% -
Launching at t = 2y 722.6 (4.3) 264.3 (5.7) 569.5 (3.6) -21.3 (5.6)
Abandon rate 53.13% - 57.34% -







Practical case v2 (new)
Simulation analysis
Hypothetical project (for every group): initial cash-flow of 100 M$ (50 M$
std dev) per quarter and initial cost to completion of 1000 M$ (std dev =
0.5)
Table: Project’s value - Panel A: With abandon option Panel B: Without abandon
option
EU BigCap EU SmallCap
Panel Panel
A B A B
Launching at t = 0y 1094.5 (5.3) 839.7 (6.10) 1486.2 (6.1) 1331.3 (6.6)
Abandon rate 37.09% - 29.22% -
Launching at t = 1y 829.6 (4.5) 458.1 (5.8) 1708.0 (6.7) 1601.2 (7.1)
Abandon rate 45.09% - 25.54% -
Launching at t = 2y 571.7 (3.6) -10.2 (5.6) 1832.2 (7.1) 1760.3 (7.5)
Abandon rate 55.49% - 23.74% -







developed a novel valuation model and methodology to value a
(pharmaceutical) R&D project based on real options approach
performed simulation analyses considering the interaction of diﬀerent
external economic and market forces
shown that the same project launched in diﬀerent countries or by diﬀerent
firms (small or large) might have diﬀerent success and abandon rates due to
the impact of the economic and industry contexts
Our research provides managers with an important tool for timing the
introduction of an R&D product to the market.
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